rheumatology
Gout

TGA strengthens febuxostat heart warning


The TGA has strengthened its warning on the use of febuxostat (Adenuric) to include all gout patients with pre-existing major cardiovascular disease. The PI for the gout drug had previously included a warning that it was not recommended for patients with ischaemic heart disease or congestive heart failure. However,  the TGA says its position has ...

Already a member?

Login to keep reading.


OR
© 2019 the limbic